Mumbai, July 29 -- Piramal Pharma Ltd will focus on increasing capacities for its contract development and manufacturing business, its largest revenue driver, even as it expects muted growth in 2025-26, chairperson Nandini Piramal said on Tuesday.

The company is aiming to double its revenues to $2 billion by 2029-30, Piramal told Mint in a post-results interview.

The Mumbai-based firm plans to spend $100-125 million in 2025 on capacity expansion. "...but even to reach our 2029-30 goals, we will have to continue to spend on capex.obviously, there is maintenance and compliance capex, but we will continue to spend on de-bottlenecking and increasing capacities where needed," Piramal said.

The company on Monday reported a 1% year-on-year de...